XBiotech Inc
NASDAQ:XBIT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Weihai Guangtai Airport Equipment Co Ltd
SZSE:002111
|
CN |
|
J
|
Jiangsu Tongxingbao Intelligent Transportation Technology Co Ltd
SZSE:301339
|
CN |
|
A
|
Alok Industries Ltd
NSE:ALOKINDS
|
IN |
|
RumbleOn Inc
NASDAQ:RMBL
|
US |
|
M
|
Maven Wireless Sweden AB
STO:MAVEN
|
SE |
XBiotech Inc
Total Current Liabilities
XBiotech Inc
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
XBiotech Inc
NASDAQ:XBIT
|
Total Current Liabilities
$7.9m
|
CAGR 3-Years
25%
|
CAGR 5-Years
15%
|
CAGR 10-Years
2%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$43.3B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$11.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$25.5B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
11%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
16%
|
CAGR 10-Years
23%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$4.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
10%
|
CAGR 10-Years
18%
|
|
XBiotech Inc
Glance View
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 97 full-time employees. The company went IPO on 2015-04-15. The firm is focused on the therapies that block a potent substance naturally produced by body, known as interleukin-1 alpha (IL-1a), that mediates tissue breakdown, angiogenesis, the formation of blood clots and inflammation. IL-1a is a protein that is on or in cells of the body and is involved in the body’s response to injury or trauma. Its True Human antibodies have the potential to harness the body's natural immunity to fight disease with increased safety, efficacy and tolerability. The firm has developed a pipeline of product candidates targeting both inflammatory and infectious diseases. The firm is developing a pipeline of product candidates targeting both inflammatory and infectious diseases and has developed commercial scale manufacturing technology and infrastructure.
See Also
What is XBiotech Inc's Total Current Liabilities?
Total Current Liabilities
7.9m
USD
Based on the financial report for Dec 31, 2025, XBiotech Inc's Total Current Liabilities amounts to 7.9m USD.
What is XBiotech Inc's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
2%
Over the last year, the Total Current Liabilities growth was -47%. The average annual Total Current Liabilities growth rates for XBiotech Inc have been 25% over the past three years , 15% over the past five years , and 2% over the past ten years .
